In vivo and in vitro anticancer activity of doxorubicin-loaded DNA-AuNP nanocarrier for the ovarian cancer treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Chang-Seuk | - |
dc.contributor.author | Kim, Tae Wan | - |
dc.contributor.author | Oh, Da Eun | - |
dc.contributor.author | Bae, Su Ok | - |
dc.contributor.author | Ryu, Jaesung | - |
dc.contributor.author | Kong, Hyejeong | - |
dc.contributor.author | Jeon, Hyeji | - |
dc.contributor.author | Seo, Hee Kyung | - |
dc.contributor.author | Jeon, Seob | - |
dc.contributor.author | Kim, Tae Hyun | - |
dc.date.accessioned | 2021-08-11T08:37:18Z | - |
dc.date.available | 2021-08-11T08:37:18Z | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/3020 | - |
dc.description.abstract | In this study, we have determined the anticancer activity of doxorubicin (Dox)-loaded DNA/gold nanoparticle (AuNP) nanocarrier (Dox-DNA-AuNP) for the treatment of ovarian cancer. The anticancer effect of Dox-DNA-AuNP was evaluated in vitro using the EZ-Cytox cell viability assay on three human ovarian cancer cell lines, SK-OV-3, HEY A8, and A2780. Dox-DNA-AuNP exhibited outstanding activity with good IC50 values of 4.8, 7.4, and 7.6 nM for SK-OV-3, HEY A8, and A2780, respectively. In vivo evaluation further demonstrated the superior anticancer effects of Dox-DNA-AuNP by inhibiting tumor growth compared to free Dox in an established SK-OV-3 xenograft mice model. Dox-DNA-AuNP showed about a 2.5 times higher tumor growth inhibition rate than free Dox. Furthermore, the immunohistochemical analysis of Ki67 antigen expression showed the lowest number of proliferative cells in the ovarian tumor tissue treated with Dox-DNA-AuNP. These results suggest Dox-DNA-AuNP might be a potential effective agent in ovarian cancer chemotherapy. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | In vivo and in vitro anticancer activity of doxorubicin-loaded DNA-AuNP nanocarrier for the ovarian cancer treatment | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/cancers12030634 | - |
dc.identifier.scopusid | 2-s2.0-85082564372 | - |
dc.identifier.wosid | 000530232300110 | - |
dc.identifier.bibliographicCitation | Cancers, v.12, no.3 | - |
dc.citation.title | Cancers | - |
dc.citation.volume | 12 | - |
dc.citation.number | 3 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | DRUG-DELIVERY SYSTEMS | - |
dc.subject.keywordPlus | GOLD-NANOPARTICLES | - |
dc.subject.keywordPlus | TARGETED DELIVERY | - |
dc.subject.keywordPlus | RELEASE | - |
dc.subject.keywordPlus | GRAPHENE | - |
dc.subject.keywordAuthor | Nanomedicine | - |
dc.subject.keywordAuthor | doxorubicin | - |
dc.subject.keywordAuthor | gold nanoparticles | - |
dc.subject.keywordAuthor | ovarian cancer | - |
dc.subject.keywordAuthor | drug delivery | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.